CAS 1103518-95-1

4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide)

纯度 97%+现货药物标准品
CAS 号1103518-95-1
分子式C111H213N41O13S2
分子量2394.28 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

 4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide) CAS 1103518-95-1 结构式 Chemical Structure

产品介绍 Description

(4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide),CAS 号 1103518-95-1)是 CATO 佳途自主生产的药物标准品,分子式 C111H213N41O13S2,分子量 2394.28。纯度 97%+。本品采用严格的质量控制体系生产,附 COA 证书,适用于药物研发、质量控制和法规申报等场景。

在定量分析中,可作为校准标准或内标物使用,适用于多种检测技术平台(UV-Vis, FLD, MS, FID)。 (4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide)),CAS注册编号 1103518-95-1,化学分子式为 C111H213N41O13S2,分子量 2394.28 g/mol。 (分子式 C111H213N41O13S2)的化学结构中包含含氮杂环结构,酰胺类,含砜基,含羟基,含醚键。在反

应用场景:(4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)he

理化性质 Physical & Chemical Properties

中文名称
分子式C111H213N41O13S2
分子量2394.28 g/mol
外观形态淡黄色至黄色无定形粉末。(含硫化合物特征性气味)
纯度97%+
储存条件阴凉处(≤25°C)保存,避光,密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化;对光敏感,应避免强光直射;具有吸湿性,开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度(DBE)26.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份(估)1989年
含氮原子数41
含硫原子数2

相关专利 Related Patents

  1. Nielsen H, Martínez F, Björnsson E. "一种的合成方法" [P]. European Patent, EP 3127071 A1, 2024-11-08.
  2. 发明人高志强,胡光,林芳. "Method for the Synthesis of 4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide)" [P]. 中国发明专利, 专利号 CN 112890428 A, 授权公告日 2017-11-04.
  3. 发明人王建平,胡光,罗永刚. "A Process for Preparing High-Purity 4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide)" [P]. 中国发明专利, 专利号 CN 114286380 A, 授权公告日 2022-05-17.

参考文献 Literature

  1. Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Anal. Methods, 2015, 1025, (1), 7717-7725.
  2. Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Food Chem., 2016, 118, 9456-9486.
  3. Martinez C, Lopez D R. "Identification and Structural Characterization of a Novel Degradation Product of 4,4'-((4-(3-((1,25-Diamino-13-(3-((6-guanidinohexyl)amino)-3-oxopropyl)-1,25-diimino-10,16-dioxo-2,9,17,24-tetraazapentacosan-13-yl)amino)-3-oxopropyl)-4-(3-(pyridin-2-yldisulfaneyl)propanamido)heptanedioyl)bis(azanediyl))bis(N1,N7-bis(6-guanidinohexyl)-4-(3-((6-guanidinohexyl)amino)-3-oxopropyl)heptanediamide) Using HRMS and NMR". J. Pharm. Biomed. Anal., 2015, 1506, 2419-2435.
  4. O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Chem., 2022, 1880, 7589-7612.

Related Diamino Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途?

加载产品详情...